Bas Van Der Baan

Bas van der Baan has over 25 years of experience in the biotechnology industry with a key focus on oncology and diagnostics. He is currently the Chief Clinical Officer of Agendia and in that role responsible for all clinical trials globally. Under his leadership more than 25,000 patients were enrolled in various clinical trials in breast cancer. Agendia has grown from a start up from the Netherlands Cancer Institute to a global company active in 30 countries with diagnostic assays fully reimbursed and included in all major clinical guidelines. Bas has extensive knowhow in the journey from clinical development to reimbursement and commercialization, as well as the establishment of partnerships with the pharmaceutical industry, academic collaborators, distributors, insurance companies and governments to successfully launch new oncology products. He co-founded ThromboDx, a liquid biopsy company for early detection of cancer, Qameleon therapeutics, a synthetic lethality company in oncology and Oncosence, an oncology drug development company using senescence as target for drug development. He is an independent member of the board at Thetis Spa, Milan.